by Fred Dumais | Sep 7, 2023 | News Release
MONTREAL, QUEBEC , September 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2023...
by Fred Dumais | Aug 31, 2023 | News Release
$3.92 million raised from non-brokered private placement offering, and $0.58 million from insider loan Investissement Québec and insiders each invest $2.0 million Proceeds from the financing to be used to strengthen working capital and support ongoing growth...
by Fred Dumais | Jul 4, 2023 | News Release
Novartis agrees to sell global rights to XIIDRA® and several other ophthalmology products to Bausch + Lomb SIMBRINZA® not included in the divestiture MONTREAL, QUEBEC, July 4, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF, FSE:VP2) (“Valeo” or the “Company”), a...
by Fred Dumais | Jun 22, 2023 | News Release
MONTREAL, QUEBEC, June 22, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the...
by Fred Dumais | Jun 13, 2023 | News Release
Sixth consecutive quarter of revenue growth at $13.6 million in Q2-23, up 184% over Q2-22. Sixth consecutive quarter of adjusted EBITDA loss reduction at $1.7 million, a 53% improvement over Q2-22, and down 24% compared to Q1-23 Physicians prescribing Enerzair and...
by Fred Dumais | Jun 7, 2023 | News Release
MONTREAL, QUEBEC , June 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2023 on...
